Compare BKSY & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | DRUG |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.7M | 856.4M |
| IPO Year | N/A | 2020 |
| Metric | BKSY | DRUG |
|---|---|---|
| Price | $21.33 | $81.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.50 | ★ $114.00 |
| AVG Volume (30 Days) | ★ 1.3M | 83.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.67 | N/A |
| Revenue Next Year | $33.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.15 | $23.18 |
| 52 Week High | $33.20 | $123.75 |
| Indicator | BKSY | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 50.32 |
| Support Level | $18.88 | $77.80 |
| Resistance Level | $22.48 | $97.75 |
| Average True Range (ATR) | 2.07 | 5.70 |
| MACD | -0.11 | 0.43 |
| Stochastic Oscillator | 55.81 | 53.95 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.